Follow the people · Insider
Helen Torley
Helen Torley files insider transactions with the SEC as a president and ceo of Halozyme Therapeutics (HALO). We hold 19 disclosed purchases and sales filed since 31 August 2011, 4 of them in the last 90 days.
- Files forHALO
- Disclosed buys and sells19 in all, 4 in the last 90 days
- Last disclosure19 August 2026
Positions held
4 posts we hold — a term names its own dates; a run of filings only says when they filed- Filed 6 January 2014 — 19 August 2026President and CEO · Halozyme Therapeutics (HALO)562 Form 4 lines · source: SEC Form 4
- Filed 15 May 2018 — 25 May 2021Director · Quest Diagnostics (DGX)7 Form 4 lines · source: SEC Form 4
- Filed 22 January 2015 — 1 September 2016Director · Relypsa (RLYP)11 Form 4 lines · source: SEC Form 4
- Filed 29 August 2011 — 1 October 2013EVP, Chief Commercial Officer · Onyx Pharmaceuticals (ONXX)46 Form 4 lines · source: SEC Form 4
Everything they disclosed
120 entries, newest first — one per disclosure report, one per Form 4 line- exercised options over 20,000 shares of Halozyme TherapeuticsSEC Form 419 August 2026Common Stock · traded 17 August 2026 · filed 19 August 2026
- ▼ sold on the open market 9,400 shares of Halozyme TherapeuticsSEC Form 419 August 2026Common Stock · traded 18 August 2026 · filed 19 August 2026
- exercised options over 20,000 shares of Halozyme TherapeuticsSEC Form 419 August 2026Common Stock · traded 19 August 2026 · filed 19 August 2026
- ▼ sold on the open market 7,200 shares of Halozyme TherapeuticsSEC Form 419 August 2026Common Stock · traded 19 August 2026 · filed 19 August 2026
- ▼ sold on the open market 9,600 shares of Halozyme TherapeuticsSEC Form 419 August 2026Common Stock · traded 19 August 2026 · filed 19 August 2026
- ▼ sold on the open market 3,200 shares of Halozyme TherapeuticsSEC Form 419 August 2026Common Stock · traded 19 August 2026 · filed 19 August 2026
- exercised options over 20,000 shares of Halozyme Therapeutics (a derivative holding)SEC Form 419 August 2026Option to Purchase Common Stock · traded 17 August 2026 · filed 19 August 2026
- exercised options over 20,000 shares of Halozyme Therapeutics (a derivative holding)SEC Form 419 August 2026Option to Purchase Common Stock · traded 18 August 2026 · filed 19 August 2026
- exercised options over 20,000 shares of Halozyme Therapeutics (a derivative holding)SEC Form 419 August 2026Option to Purchase Common Stock · traded 19 August 2026 · filed 19 August 2026
- ▼ sold on the open market 900 shares of Halozyme TherapeuticsSEC Form 419 August 2026Common Stock · traded 17 August 2026 · filed 19 August 2026
- ▼ sold on the open market 500 shares of Halozyme TherapeuticsSEC Form 419 August 2026Common Stock · traded 17 August 2026 · filed 19 August 2026
- ▼ sold on the open market 2,100 shares of Halozyme TherapeuticsSEC Form 419 August 2026Common Stock · traded 17 August 2026 · filed 19 August 2026
- ▼ sold on the open market 9,000 shares of Halozyme TherapeuticsSEC Form 419 August 2026Common Stock · traded 17 August 2026 · filed 19 August 2026
- ▼ sold on the open market 7,500 shares of Halozyme TherapeuticsSEC Form 419 August 2026Common Stock · traded 17 August 2026 · filed 19 August 2026
- exercised options over 20,000 shares of Halozyme TherapeuticsSEC Form 419 August 2026Common Stock · traded 18 August 2026 · filed 19 August 2026
- ▼ sold on the open market 5,703 shares of Halozyme TherapeuticsSEC Form 419 August 2026Common Stock · traded 18 August 2026 · filed 19 August 2026
- ▼ sold on the open market 4,897 shares of Halozyme TherapeuticsSEC Form 419 August 2026Common Stock · traded 18 August 2026 · filed 19 August 2026
- exercised options over 1,923 shares of Halozyme TherapeuticsSEC Form 49 July 2026Common Stock · traded 8 July 2026 · filed 9 July 2026
- ▼ sold on the open market 888 shares of Halozyme TherapeuticsSEC Form 49 July 2026Common Stock · traded 8 July 2026 · filed 9 July 2026
- ▼ sold on the open market 1,035 shares of Halozyme TherapeuticsSEC Form 49 July 2026Common Stock · traded 8 July 2026 · filed 9 July 2026
- exercised options over 1,923 shares of Halozyme Therapeutics (a derivative holding)SEC Form 49 July 2026Option to Purchase Common Stock · traded 8 July 2026 · filed 9 July 2026
- exercised options over 20,000 shares of Halozyme TherapeuticsSEC Form 43 June 2026Common Stock · traded 1 June 2026 · filed 3 June 2026
- ▼ sold on the open market 1,500 shares of Halozyme TherapeuticsSEC Form 43 June 2026Common Stock · traded 3 June 2026 · filed 3 June 2026
- ▼ sold on the open market 2,000 shares of Halozyme TherapeuticsSEC Form 43 June 2026Common Stock · traded 3 June 2026 · filed 3 June 2026
- ▼ sold on the open market 6,100 shares of Halozyme TherapeuticsSEC Form 43 June 2026Common Stock · traded 3 June 2026 · filed 3 June 2026
- exercised options over 20,000 shares of Halozyme Therapeutics (a derivative holding)SEC Form 43 June 2026Option to Purchase Common Stock · traded 1 June 2026 · filed 3 June 2026
- exercised options over 20,000 shares of Halozyme Therapeutics (a derivative holding)SEC Form 43 June 2026Option to Purchase Common Stock · traded 2 June 2026 · filed 3 June 2026
- exercised options over 10,000 shares of Halozyme Therapeutics (a derivative holding)SEC Form 43 June 2026Option to Purchase Common Stock · traded 3 June 2026 · filed 3 June 2026
- ▼ sold on the open market 1,610 shares of Halozyme TherapeuticsSEC Form 43 June 2026Common Stock · traded 1 June 2026 · filed 3 June 2026
- ▼ sold on the open market 12,989 shares of Halozyme TherapeuticsSEC Form 43 June 2026Common Stock · traded 1 June 2026 · filed 3 June 2026
- ▼ sold on the open market 5,401 shares of Halozyme TherapeuticsSEC Form 43 June 2026Common Stock · traded 1 June 2026 · filed 3 June 2026
- exercised options over 20,000 shares of Halozyme TherapeuticsSEC Form 43 June 2026Common Stock · traded 2 June 2026 · filed 3 June 2026
- ▼ sold on the open market 16,600 shares of Halozyme TherapeuticsSEC Form 43 June 2026Common Stock · traded 2 June 2026 · filed 3 June 2026
- ▼ sold on the open market 3,400 shares of Halozyme TherapeuticsSEC Form 43 June 2026Common Stock · traded 2 June 2026 · filed 3 June 2026
- exercised options over 10,000 shares of Halozyme TherapeuticsSEC Form 43 June 2026Common Stock · traded 3 June 2026 · filed 3 June 2026
- ▼ sold on the open market 400 shares of Halozyme TherapeuticsSEC Form 43 June 2026Common Stock · traded 3 June 2026 · filed 3 June 2026
- exercised options over 20,000 shares of Halozyme TherapeuticsSEC Form 413 May 2026Common Stock · traded 11 May 2026 · filed 13 May 2026
- ▼ sold on the open market 2,800 shares of Halozyme TherapeuticsSEC Form 413 May 2026Common Stock · traded 12 May 2026 · filed 13 May 2026
- exercised options over 10,000 shares of Halozyme TherapeuticsSEC Form 413 May 2026Common Stock · traded 13 May 2026 · filed 13 May 2026
- ▼ sold on the open market 2,100 shares of Halozyme TherapeuticsSEC Form 413 May 2026Common Stock · traded 13 May 2026 · filed 13 May 2026
- ▼ sold on the open market 3,350 shares of Halozyme TherapeuticsSEC Form 413 May 2026Common Stock · traded 13 May 2026 · filed 13 May 2026
- ▼ sold on the open market 3,950 shares of Halozyme TherapeuticsSEC Form 413 May 2026Common Stock · traded 13 May 2026 · filed 13 May 2026
- ▼ sold on the open market 600 shares of Halozyme TherapeuticsSEC Form 413 May 2026Common Stock · traded 13 May 2026 · filed 13 May 2026
- exercised options over 20,000 shares of Halozyme Therapeutics (a derivative holding)SEC Form 413 May 2026Option to Purchase Common Stock · traded 11 May 2026 · filed 13 May 2026
- exercised options over 20,000 shares of Halozyme Therapeutics (a derivative holding)SEC Form 413 May 2026Option to Purchase Common Stock · traded 12 May 2026 · filed 13 May 2026
- exercised options over 10,000 shares of Halozyme Therapeutics (a derivative holding)SEC Form 413 May 2026Option to Purchase Common Stock · traded 13 May 2026 · filed 13 May 2026
- ▼ sold on the open market 9,725 shares of Halozyme TherapeuticsSEC Form 413 May 2026Common Stock · traded 11 May 2026 · filed 13 May 2026
- ▼ sold on the open market 3,575 shares of Halozyme TherapeuticsSEC Form 413 May 2026Common Stock · traded 11 May 2026 · filed 13 May 2026
- ▼ sold on the open market 6,700 shares of Halozyme TherapeuticsSEC Form 413 May 2026Common Stock · traded 11 May 2026 · filed 13 May 2026
- exercised options over 20,000 shares of Halozyme TherapeuticsSEC Form 413 May 2026Common Stock · traded 12 May 2026 · filed 13 May 2026
- ▼ sold on the open market 100 shares of Halozyme TherapeuticsSEC Form 413 May 2026Common Stock · traded 12 May 2026 · filed 13 May 2026
- ▼ sold on the open market 1,398 shares of Halozyme TherapeuticsSEC Form 413 May 2026Common Stock · traded 12 May 2026 · filed 13 May 2026
- ▼ sold on the open market 9,802 shares of Halozyme TherapeuticsSEC Form 413 May 2026Common Stock · traded 12 May 2026 · filed 13 May 2026
- ▼ sold on the open market 5,900 shares of Halozyme TherapeuticsSEC Form 413 May 2026Common Stock · traded 12 May 2026 · filed 13 May 2026
- exercised options over 10,000 shares of Halozyme TherapeuticsSEC Form 47 April 2026Common Stock · traded 6 April 2026 · filed 7 April 2026
- ▼ sold on the open market 5,900 shares of Halozyme TherapeuticsSEC Form 47 April 2026Common Stock · traded 6 April 2026 · filed 7 April 2026
- ▼ sold on the open market 4,100 shares of Halozyme TherapeuticsSEC Form 47 April 2026Common Stock · traded 6 April 2026 · filed 7 April 2026
- exercised options over 10,000 shares of Halozyme Therapeutics (a derivative holding)SEC Form 47 April 2026Option to Purchase Common Stock · traded 6 April 2026 · filed 7 April 2026
- exercised options over 20,000 shares of Halozyme TherapeuticsSEC Form 42 April 2026Common Stock · traded 1 April 2026 · filed 2 April 2026
- ▼ sold on the open market 19,000 shares of Halozyme TherapeuticsSEC Form 42 April 2026Common Stock · traded 1 April 2026 · filed 2 April 2026
- ▼ sold on the open market 1,000 shares of Halozyme TherapeuticsSEC Form 42 April 2026Common Stock · traded 1 April 2026 · filed 2 April 2026
- exercised options over 20,000 shares of Halozyme TherapeuticsSEC Form 42 April 2026Common Stock · traded 2 April 2026 · filed 2 April 2026
- ▼ sold on the open market 15,800 shares of Halozyme TherapeuticsSEC Form 42 April 2026Common Stock · traded 2 April 2026 · filed 2 April 2026
- ▼ sold on the open market 4,200 shares of Halozyme TherapeuticsSEC Form 42 April 2026Common Stock · traded 2 April 2026 · filed 2 April 2026
- exercised options over 20,000 shares of Halozyme Therapeutics (a derivative holding)SEC Form 42 April 2026Option to Purchase Common Stock · traded 1 April 2026 · filed 2 April 2026
- exercised options over 20,000 shares of Halozyme Therapeutics (a derivative holding)SEC Form 42 April 2026Option to Purchase Common Stock · traded 2 April 2026 · filed 2 April 2026
- exercised options over 20,000 shares of Halozyme TherapeuticsSEC Form 44 March 2026Common Stock · traded 2 March 2026 · filed 4 March 2026
- ▼ sold on the open market 2,671 shares of Halozyme TherapeuticsSEC Form 44 March 2026Common Stock · traded 4 March 2026 · filed 4 March 2026
- exercised options over 20,000 shares of Halozyme Therapeutics (a derivative holding)SEC Form 44 March 2026Option to Purchase Common Stock · traded 2 March 2026 · filed 4 March 2026
- exercised options over 20,000 shares of Halozyme Therapeutics (a derivative holding)SEC Form 44 March 2026Option to Purchase Common Stock · traded 3 March 2026 · filed 4 March 2026
- exercised options over 10,000 shares of Halozyme Therapeutics (a derivative holding)SEC Form 44 March 2026Option to Purchase Common Stock · traded 4 March 2026 · filed 4 March 2026
- ▼ sold on the open market 4,100 shares of Halozyme TherapeuticsSEC Form 44 March 2026Common Stock · traded 2 March 2026 · filed 4 March 2026
- ▼ sold on the open market 15,322 shares of Halozyme TherapeuticsSEC Form 44 March 2026Common Stock · traded 2 March 2026 · filed 4 March 2026
- exercised options over 20,000 shares of Halozyme Therapeutics (a derivative holding)SEC Form 44 March 2026Option to Purchase Common Stock · traded 2 March 2026 · filed 4 March 2026
- exercised options over 20,000 shares of Halozyme Therapeutics (a derivative holding)SEC Form 44 March 2026Option to Purchase Common Stock · traded 3 March 2026 · filed 4 March 2026
- exercised options over 10,000 shares of Halozyme Therapeutics (a derivative holding)SEC Form 44 March 2026Option to Purchase Common Stock · traded 4 March 2026 · filed 4 March 2026
- ▼ sold on the open market 578 shares of Halozyme TherapeuticsSEC Form 44 March 2026Common Stock · traded 2 March 2026 · filed 4 March 2026
- exercised options over 20,000 shares of Halozyme TherapeuticsSEC Form 44 March 2026Common Stock · traded 3 March 2026 · filed 4 March 2026
- ▼ sold on the open market 13,481 shares of Halozyme TherapeuticsSEC Form 44 March 2026Common Stock · traded 3 March 2026 · filed 4 March 2026
- ▼ sold on the open market 6,519 shares of Halozyme TherapeuticsSEC Form 44 March 2026Common Stock · traded 3 March 2026 · filed 4 March 2026
- exercised options over 10,000 shares of Halozyme TherapeuticsSEC Form 44 March 2026Common Stock · traded 4 March 2026 · filed 4 March 2026
- exercised options over 20,000 shares of Halozyme TherapeuticsSEC Form 44 March 2026Common Stock · traded 2 March 2026 · filed 4 March 2026
- ▼ sold on the open market 4,100 shares of Halozyme TherapeuticsSEC Form 44 March 2026Common Stock · traded 2 March 2026 · filed 4 March 2026
- ▼ sold on the open market 15,322 shares of Halozyme TherapeuticsSEC Form 44 March 2026Common Stock · traded 2 March 2026 · filed 4 March 2026
- ▼ sold on the open market 578 shares of Halozyme TherapeuticsSEC Form 44 March 2026Common Stock · traded 2 March 2026 · filed 4 March 2026
- exercised options over 20,000 shares of Halozyme TherapeuticsSEC Form 44 March 2026Common Stock · traded 3 March 2026 · filed 4 March 2026
- ▼ sold on the open market 13,481 shares of Halozyme TherapeuticsSEC Form 44 March 2026Common Stock · traded 3 March 2026 · filed 4 March 2026
- ▼ sold on the open market 6,519 shares of Halozyme TherapeuticsSEC Form 44 March 2026Common Stock · traded 3 March 2026 · filed 4 March 2026
- exercised options over 10,000 shares of Halozyme TherapeuticsSEC Form 44 March 2026Common Stock · traded 4 March 2026 · filed 4 March 2026
- ▼ sold on the open market 7,329 shares of Halozyme TherapeuticsSEC Form 44 March 2026Common Stock · traded 4 March 2026 · filed 4 March 2026
- ▼ sold on the open market 2,671 shares of Halozyme TherapeuticsSEC Form 44 March 2026Common Stock · traded 4 March 2026 · filed 4 March 2026
- ▼ sold on the open market 7,329 shares of Halozyme TherapeuticsSEC Form 44 March 2026Common Stock · traded 4 March 2026 · filed 4 March 2026
- exercised options over 16,757 shares of Halozyme TherapeuticsSEC Form 424 February 2026Common Stock · traded 20 February 2026 · filed 24 February 2026
- had shares withheld for tax on 9,040 shares of Halozyme TherapeuticsSEC Form 424 February 2026Common Stock · traded 20 February 2026 · filed 24 February 2026
- exercised options over 22,436 shares of Halozyme TherapeuticsSEC Form 424 February 2026Common Stock · traded 23 February 2026 · filed 24 February 2026
- exercised options over 16,757 shares of Halozyme Therapeutics (a derivative holding)SEC Form 424 February 2026Restricted Stock Units · traded 20 February 2026 · filed 24 February 2026
- exercised options over 22,436 shares of Halozyme Therapeutics (a derivative holding)SEC Form 424 February 2026Restricted Stock Units · traded 23 February 2026 · filed 24 February 2026
- had shares withheld for tax on 12,104 shares of Halozyme TherapeuticsSEC Form 424 February 2026Common Stock · traded 23 February 2026 · filed 24 February 2026
- exercised options over 16,757 shares of Halozyme Therapeutics (a derivative holding)SEC Form 424 February 2026Restricted Stock Units · traded 20 February 2026 · filed 24 February 2026
- exercised options over 22,436 shares of Halozyme Therapeutics (a derivative holding)SEC Form 424 February 2026Restricted Stock Units · traded 23 February 2026 · filed 24 February 2026
- exercised options over 16,757 shares of Halozyme TherapeuticsSEC Form 424 February 2026Common Stock · traded 20 February 2026 · filed 24 February 2026
- had shares withheld for tax on 9,040 shares of Halozyme TherapeuticsSEC Form 424 February 2026Common Stock · traded 20 February 2026 · filed 24 February 2026
- exercised options over 22,436 shares of Halozyme TherapeuticsSEC Form 424 February 2026Common Stock · traded 23 February 2026 · filed 24 February 2026
- had shares withheld for tax on 12,104 shares of Halozyme TherapeuticsSEC Form 424 February 2026Common Stock · traded 23 February 2026 · filed 24 February 2026
- exercised options over 21,009 shares of Halozyme TherapeuticsSEC Form 417 February 2026Common Stock · traded 16 February 2026 · filed 17 February 2026
- had shares withheld for tax on 11,334 shares of Halozyme TherapeuticsSEC Form 417 February 2026Common Stock · traded 16 February 2026 · filed 17 February 2026
- exercised options over 16,875 shares of Halozyme TherapeuticsSEC Form 417 February 2026Common Stock · traded 16 February 2026 · filed 17 February 2026
- exercised options over 21,009 shares of Halozyme Therapeutics (a derivative holding)SEC Form 417 February 2026Restricted Stock Units · traded 16 February 2026 · filed 17 February 2026
- exercised options over 16,875 shares of Halozyme Therapeutics (a derivative holding)SEC Form 417 February 2026Restricted Stock Units · traded 16 February 2026 · filed 17 February 2026
- exercised options over 51,171 shares of Halozyme Therapeutics (a derivative holding)SEC Form 417 February 2026Performance Stock Units · traded 16 February 2026 · filed 17 February 2026
- had shares withheld for tax on 9,104 shares of Halozyme TherapeuticsSEC Form 417 February 2026Common Stock · traded 16 February 2026 · filed 17 February 2026
- exercised options over 51,171 shares of Halozyme TherapeuticsSEC Form 417 February 2026Common Stock · traded 16 February 2026 · filed 17 February 2026
- had shares withheld for tax on 27,605 shares of Halozyme TherapeuticsSEC Form 417 February 2026Common Stock · traded 16 February 2026 · filed 17 February 2026
- exercised options over 21,009 shares of Halozyme Therapeutics (a derivative holding)SEC Form 417 February 2026Restricted Stock Units · traded 16 February 2026 · filed 17 February 2026
- exercised options over 16,875 shares of Halozyme Therapeutics (a derivative holding)SEC Form 417 February 2026Restricted Stock Units · traded 16 February 2026 · filed 17 February 2026
- exercised options over 21,009 shares of Halozyme TherapeuticsSEC Form 417 February 2026Common Stock · traded 16 February 2026 · filed 17 February 2026
- had shares withheld for tax on 11,334 shares of Halozyme TherapeuticsSEC Form 417 February 2026Common Stock · traded 16 February 2026 · filed 17 February 2026
- exercised options over 16,875 shares of Halozyme TherapeuticsSEC Form 417 February 2026Common Stock · traded 16 February 2026 · filed 17 February 2026
- had shares withheld for tax on 9,104 shares of Halozyme TherapeuticsSEC Form 417 February 2026Common Stock · traded 16 February 2026 · filed 17 February 2026
- exercised options over 51,171 shares of Halozyme TherapeuticsSEC Form 417 February 2026Common Stock · traded 16 February 2026 · filed 17 February 2026
Positions come from the unitedstates/congress-legislators roster, the Office of Government Ethics and the SEC’s Form 4 index. Every disclosed line names its own source and links the document the government published; we print what the filing says and never a price we did not read from it. Headlines and links come from the GDELT Global Knowledge Graph — the story stays with the publisher. The portrait, where we have one, is the public-domain Congressional Bioguide photograph.